Provided is a composition for treating obesity which comprises an effective amount of a prostaglandin compound, especially, a compound of formula (I). ##STR00001##

Sucampo AG

Prostaglandin compounds for the treatment of obesity

Disclosed are methods and compositions for treating pulmonary arterial hypertension and/or obesity using inhibitors of prostaglandin transporter (PGT) activity.

ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.

Albert Einstein College of Medicine, Inc.

Treatment of obesity and pulmonary arterial hypertension

The present application provides a human gene over-expressing animal, which is a non-human animal carrying a human hematopoietic prostaglandin D.sub.2 synthase gene in its somatic cell chromosome and expressing a large amount of human prostaglandin D.sub.2 synthase, wherein the animal is one obtained through ontogenesis of a totipotency cell of a non-human animal or offspring of the obtained animal, and the totipotency cell is introduced with said synthase gene. The present application also provides a method of using the transgenic animal for testing in vivo activity of a candidate for anti-allergy medicines, sleep-controlling substances and candidates for anti-obesity.

Japan Science and Technology Corporation

Osaka Bioscience Institute

Oriental Yeast Co., Ltd.

Animal with the mass expression of human gene and test method by using the animal